Morgan Stanley analyst Patrick Wood downgraded Glaukos (GKOS) to Underweight from Equal Weight with a $120 price target While the firm thinks iDose is “a great product with a long-term trajectory,” it is struggling to see relative upside from here versus others stocks based on the current valuation. While there are also some “great assets in the pipeline,” these are some time out, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS: